A Safety, Tolerability, and Biomarker Trial of VS-041 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Cardiology and Medicine Clinic, Little Rock, Arkansas, United States

National Institute of Clinical Research, Huntington Beach, California, United States

FOMAT, Santa Maria, California, United States

Invivocure LLC, Van Nuys, California, United States

New Generation of Medical Research, Hialeah, Florida, United States

Jacksonville Center for Clinical Research, Jacksonville, Florida, United States

Amavita Health, North Miami Beach, Florida, United States

Broward Research Center, Pembroke Pines, Florida, United States

Eagle Clinical Research, Chicago, Illinois, United States

Chicago Medical Research, Hazel Crest, Illinois, United States

Methodist Medical Center of Illinois, Peoria, Illinois, United States

Louisiana Heart Center, Slidell, Louisiana, United States

Washington University, St Louis, Missouri, United States

Ash Research Clinic, Brick, New Jersey, United States

Erie County Medical Center, Buffalo, New York, United States

Duke University Medical Center, Durham, North Carolina, United States

Wake Forest, Winston-Salem, North Carolina, United States

Cleveland Clinic, Cleveland, Ohio, United States

Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States

University of Texas Southwestern Medical Center, Dallas, Texas, United States

LinQ Research, LLC, Tomball, Texas, United States